Libra Review | Choose Better

You can view the original post here Saturday, Might 7, 2022 On the 2022 European Congress on Obesity , which I attended over the previous couple of days, there was a lot buzz in regards to the fairly spectacular 22% average weight loss achieved with the dual GIP-GLP-1 agonist tirzepatide – a level of weight reduction that isn't removed from matching the weight-loss outcomes of sufferers present process metabolic surgical procedure. Clearly these outcomes  are shifting the benchmark for what we are able to count on from future anti-obesity drugs.  Whereas we await the total publication of those outcomes and the outcomes of the opposite trials within the SURMOUNT program, it could be prudent to take a position what these outcomes imply for compounds and remedy choices for weight problems presently within the pipeline.  Finally rely, there have been over twenty completely different anti-obesity compounds throughout a variety of modes of motio...

Wednesday, December 1, 2021 I've been practising drugs lengthy sufficient to recollect treating hypertension earlier than there have been ACE inhibitors or ARBs. I vividly bear in mind coaching in a lipid clinic earlier than the introduction of statins. Many will recall managing sort 2 diabetes earlier than we had TZDs, DPP4 inhibitors, SGLT2 blockers, or GLP-1 analogues.  In all of those illness areas, previous to the introduction of the at present accessible efficient drugs, the main focus was on dietary and different behavioural interventions.  Thus, I recall giving talks on sodium restriction, bodily exercise, or the DASH food plan for managing hypertension or on the AHA Step I/II diets to handle dyslipidemia. Whereas dietary and different behavioural interventions stay vital pillars for managing these situations, it could be fairly unusual right this moment to see clinicians handle any of those entities with “lifestyle” interventions alone.  ...